eFigure 2.

Sustained virologic response rates in the ADVANCE study for treatment-naive patients with HCV genotype 1 (19)

Patients received telaprevir combined with peginterferon alfa-2b/ribavirin for 8 or 12 weeks, followed by dual peginterferon/ribavirin treatment for a total of 24 to 48 weeks (TVR for 12 weeks + pegIFN/RBV for 24 or 48 weeks, or TVR for 8 weeks + pegIFN/RBV for 24 or 48 weeks). Treatment was shortened to 24 weeks if rapid virologic response (no evidence of HCV-RNA at weeks 4 and 12) was achieved. Patients in the control group received peginterferon/ribavirin for 48 weeks (pegIFN/RBV for 48 weeks)